Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Biotechnology  // Browsing posts in Biotechnology

Indivior’s Sublocade Idea Proposal (INDV)

Indivior’s Sublocade Idea Proposal (INDV)

Is the launch of Indivior’s Sublocade on track? Is the treatment community ready to adopt Sublocade? Report Available: July 12, 2018   Blueshift’s initial research found INDV highly optimistic about its recently approved drug Sublocade, a monthly injection of buprenorphine used to treat Opioid Use Disorder (OUD). The product is in the early stages of launch […]

Read more...

Exact Sciences Idea Proposal (EXAS)

Exact Sciences Idea Proposal (EXAS)

Will demand for Cologuard tests continue to surge and drive growth for Exact Sciences?   Report Available: December 7, 2017   Blueshift’s ongoing research shows the use of EXAS’ Cologuard test for colorectal cancer screening continuing to gain traction with patients and physicians. Cologuard is picking up endorsements from the medical community and contracts with insurers, […]

Read more...

Camurus and Indivior Set to Significantly Sway the Opioid Abuse Treatment Market (INDV)

Research Question: How will the new long-acting buprenorphine options and changing government rules affect the opioid abuse treatment market? Companies: ALKS, DEPO, LON:INDV, STO:CAMX, STO:ORX, TTNP By: David Franklin Click here to download report (.pdf)   Summary of Findings Weekly and monthly injectable buprenorphine treatments that could significantly affect the medication-assisted treatment (MAT) market for […]

Read more...

HEDIS Will Create Modest Growth for Exact Sciences’ Cologuard (EXAS)

Research Question: Will the inclusion of Cologuard in the 2017 HEDIS quality measures drive growth for Exact Sciences? Companies: DGX, EPGNF, EXAS, GE, LH, SIEGY, TYO:6502 By: David Franklin Click here to download report (.pdf)   Summary of Findings The inclusion and equal footing of Exact Sciences Corp.’s (EXAS) Cologuard in the 2017 Healthcare Effectiveness Data […]

Read more...

Exact Sciences Idea Proposal (EXAS)

Exact Sciences Idea Proposal (EXAS)

Will the inclusion of Cologuard in the 2017 HEDIS quality measures drive growth for Exact Sciences? Report Available:August 31, 2016   Blueshift’s initial research shows that momentum for Cologuard, EXAS’s colon cancer screening test, has picked up recently as a governing body clarified language that the test is on equal standing among other screening tests, […]

Read more...

Jun 24 2016 Biotechnology, Healthcare

NVDQ’s DermACELL On Track to Achieve 2016 Sales Goal of $10 Million

Research Question: Will Novadaq grow DermACELL sales to $10 million in 2016 and $50 million or more by 2018? Companies: AGN, IART, JNJ, MDXG, NVDQ, NVS, OSIR By: David Franklin Click here to download the report (.pdf)   Summary of Findings DermACELL, an acellular dermal matrix (ADM) tissue that is used primarily in breast reconstruction, is likely […]

Read more...

Novadaq Idea Proposal

Novadaq Idea Proposal

Will Novadaq successfully grow DermACELL sales to $50 million or more by 2018? Report Available: June 23, 2016   Blueshift’s initial research shows sales of NVDQ’s DermACELL, its acellular dermal matrix (ADM) product used primarily in breast reconstruction, increasing as it becomes part of the company’s fastest growing segment. Management expects it to reach about $10 […]

Read more...

Buprenorphine Opioid Addiction Treatment Idea Proposal

Buprenorphine Opioid Addiction Treatment Idea Proposal

Will long acting implantable and injectable buprenorphine become widely adopted for opioid addiction treatment? Report Available: April 8, 2016   Blueshift’s initial research shows that addiction to opioids has skyrocketed to the point of being an epidemic. Current available treatment options face numerous challenges including frequent dosing, poor adherence, high incidence of relapse, and misuse. […]

Read more...

Exact Sciences’ Cologuard the Preferred Test for Patients Refusing Colonoscopy (EXAS)

Research Question: Will Exact Sciences’ Cologuard become physician’s screening test of choice for colon cancer? Companies: ABT, BDX, BIOC, BSX, CHEK, CPHD, DGX, EXAS, FMI, GIVN, GSK, IRWD, RHHBY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Exact Sciences Corp.’s (EXAS) Cologuard has high clinical value, but it is unlikely […]

Read more...

Exact Sciences Whisper

Exact Sciences Whisper

Research Question: Will Exact Sciences’ Cologuard become the colon cancer screening test of choice for physicians? Report Available: August 14, 2015   Blueshift’s initial research shows EXAS’s Cologuard, a non-invasive test for colon cancer, is monetizing at a significant rate following FDA approval and an increased sales staff. But some physicians argue the screener should not be […]

Read more...